Dorsey & Whitney Trust CO LLC Lowers Holdings in Eli Lilly and Company $LLY

Key Points

• Dorsey & Whitney Trust CO LLC has reduced its stake in Eli Lilly and Company by 1.8%, now holding 48,701 shares valued at approximately $40.22 million.
• Several institutional investors, including WestEnd Advisors LLC and Citizens National Bank Trust Department, have significantly increased their positions in Eli Lilly during the first quarter of the year.
• Analysts have mixed ratings for Eli Lilly stock, with price targets ranging from $700 to $1,135, and a majority rating it as a "Buy" or "Moderate Buy."

Dorsey & Whitney Trust CO LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,701 shares of the company's stock after selling 901 shares during the quarter. Eli Lilly and Company makes up about 2.3% of Dorsey & Whitney Trust CO LLC's holdings, making the stock its 5th biggest holding. Dorsey & Whitney Trust CO LLC's holdings in Eli Lilly and Company were worth $40,223,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Knollwood Investment Advisory LLC increased its position in Eli Lilly and Company by 6.3% during the 1st quarter. Knollwood Investment Advisory LLC now owns 12,299 shares of the company's stock valued at $10,158,000 after purchasing an additional 728 shares during the period. Aspire Growth Partners LLC increased its position in Eli Lilly and Company by 5.0% during the 1st quarter. Aspire Growth Partners LLC now owns 1,212 shares of the company's stock valued at $941,000 after purchasing an additional 58 shares during the period. GM Advisory Group LLC increased its position in Eli Lilly and Company by 4.8% during the 1st quarter. GM Advisory Group LLC now owns 11,938 shares of the company's stock valued at $9,859,000 after purchasing an additional 552 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Eli Lilly and Company by 41.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,115,376 shares of the company's stock valued at $921,201,000 after purchasing an additional 324,598 shares during the period. Finally, Frisch Financial Group Inc. increased its position in Eli Lilly and Company by 2.1% during the 1st quarter. Frisch Financial Group Inc. now owns 2,106 shares of the company's stock valued at $1,740,000 after purchasing an additional 44 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Leerink Partners reissued a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $950.17.

Insider Buying and Selling

In other news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 over the last quarter. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 0.5%

Shares of NYSE:LLY traded up $3.3830 during midday trading on Thursday, reaching $708.8230. The company's stock had a trading volume of 3,611,878 shares, compared to its average volume of 6,931,770. The firm has a 50 day moving average of $756.85 and a 200-day moving average of $791.70. The firm has a market capitalization of $670.87 billion, a P/E ratio of 46.33, a PEG ratio of 0.98 and a beta of 0.44. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.